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Epistasis with HLA DR3 implicates the P2X7
receptor in the pathogenesis of primary Sjögren’s
syndrome
Susan Lester1, Leanne Stokes2,3, Kristen K Skarratt2, Ben J Gu2,4, Kathy L Sivils5, Christopher J Lessard5,
James S Wiley2,4† and Maureen Rischmueller1,6*†
Abstract
Introduction: The aim of this study was to examine the association between functional polymorphisms in the pro-
inflammatory P2X7 receptor and the Ro/La autoantibody response in primary Sjögren’s syndrome (pSS).
Methods: Twelve functional P2RX7 polymorphisms were genotyped in 114 pSS patients fulfilling the Revised
American-European Consensus Criteria for pSS, and 136 controls. Genotyping of the A1405G (rs2230912)
polymorphism was performed on a replication cohort consisting of 281 pSS patients and 534 controls. P2X7
receptor function in lymphocytes and monocytes was assessed by measurement of ATP-induced ethidium+
uptake. Serum IL-18 levels were determined by ELISA.
Results: The minor allele of P2RX7 A1405G is a tag for a common haplotype associated with gain in receptor
function, as assessed by ATP-induced ethidium+ uptake. A positive association between 1405G and anti-Ro±La
seropositive pSS patients was observed in Cohort 1. Although not replicated in Cohort 2, there was a consistent,
significant, negative epistatic interaction effect with HLA-DR3 in seropositive pSS patients from both cohorts,
thereby implicating this gain of function variant in the pathogenesis of pSS. Serum IL-18 was elevated in
seropositive pSS patients, but was not influenced by P2RX7 A1405G.
Conclusions: The P2RX7 1405G gain-of-function haplotype may be a risk factor for seropositive pSS in a subset of
subjects who do not carry HLA risk alleles, but has no effect in subjects who do (epistasis). Potential mechanisms
relate to autoantigen exposure and inflammatory cytokine expression. The observed elevation of IL-18 levels is
consistent with P2X7 receptor activation in seropositive pSS patients. Collectively these findings implicate P2X7
receptor function in the pathogenesis of pSS.
 
Introduction
Primary Sjögren’s syndrome (pSS) is a systemic autoim-
mune disease characterized by lymphocytic and monocy-
tic infiltration into the salivary and lacrimal glands with
inflammation, destruction of acini and failure of exocrine
secretion. A wide range of extraglandular features also
manifest in a subset of patients. Autoantibodies targeting
the Ro and La components of a ribonucleoprotein (RNP)
complex are highly specific for pSS and constitute one of
the classification criteria for this disease [1]. Once con-
sidered an epiphenomenon, these autoantibodies are now
recognized to be involved in the systemic inflammation
of pSS [2].
A substantial polygenic component underlies suscept-
ibility to the Ro/La autoantibody response in pSS [3,4],
however the strongest individual association is observed
with HLA-DRB1*03:01 (DR3, Chr 6p21.3) [5]. Additional
genes are also likely to be involved, and one candidate is
the P2X7 receptor (Chr 12q24.31), whose chromosomal
location lies within mapped human and murine systemic
lupus erythematosus (SLE) susceptibility loci [6]. The
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purinergic P2X7 receptor has been implicated in several
murine models of autoimmune disease, including experi-
mental autoimmune encephalomyelitis [7], rheumatoid
arthritis (RA) [8] and autoimmune hepatitis [9].
The P2X7 receptor belongs to a two-transmembrane
family of receptors, which are trimeric in the membrane
and are attached via non-muscle myosin to the actin
cytoskeleton [10-12]. Activation of P2X7, in response to
the binding of extracellular ATP, opens a non-selective
cation channel allowing an immediate influx of Ca2+
and Na+, and efflux of K+ ions. Continued activation,
over tens of seconds, allows a larger permeability state
to develop (termed pore formation), which is accompa-
nied by extensive membrane blebbing, and ultimately
cell death, with features of both apoptosis and necrosis
[13,14]. Extracellular ATP is normally maintained at low
nanomolar levels by a ubiquitous ecto-ATPDase (CD39),
although in an inflammatory milieu, ATP may be released
from dead or injured cells, as well as by cell swelling or
from autonomic nerves [15].
The P2X7 receptor is found on many cells and tissues
throughout the body. The receptor is most highly
expressed on cells of the macrophage lineage, including
dendritic cells and microglia [13,16], and both P2X7
receptors and HLA Class II molecules are upregulated in
parallel when monocytes differentiate to these mature cell
types. P2X7 receptors are also abundant on both acinar
and ductal cells from submandibular and other salivary
glands [17,18]. A special role for this receptor in salivary
glands has been highlighted by its direct involvement in
the regulation of fluid secretion [19,20]. In cells of the
monocyte-macrophage lineage, there is much evidence
that P2X7 is pro-inflammatory [16,21], and P2X7 gene-
deleted mice show major reductions in cytokine responses
to various inflammatory stimuli [8]. Activation of the
P2X7 receptor results in maturation and release of the
pro-inflammatory cytokines, IL-1b and IL-18 [21-23], a
response that has been linked to formation of the cryo-
pyrin (NALP3) inflammasome and subsequent caspase-1
activation [21,24]. Elevated serum levels of both IL-1b and
IL-18 have been reported in pSS [25,26], and these cyto-
kines have been implicated in salivary gland pathology in
both mouse models [27] and human disease [28,29].
There is considerable variability in P2X7 function
between individuals, which can be largely attributed to
polymorphisms of the P2RX7 gene. To date, one dozen
polymorphisms have been identified in P2RX7, which
alter receptor function [30,31]. We and others have
shown that polymorphisms that increase or decrease
P2X7 receptor function confer a corresponding increase
or decrease in ATP-stimulated secretion of IL-1b or IL-
18 from monocytes primed with lipopolysaccharide
[31-33]. We have now examined these functional P2RX7
SNPs in patients with pSS, and have identified an
epistatic interaction between the major P2RX7 gain-of-
function haplotype and HLA-DR3 in patients with sero-
positive pSS.
Materials and methods
Study participants
Cohort 1 included 114 Caucasian pSS patients (88%
female) from the South Australian Sjögren’s Syndrome
research registry, and 136 Caucasian population-based
controls. The replication cohort (cohort 2) included 281
Caucasian pSS patients (95% female) obtained from the
Oklahoma Medical Research Foundation (OMRF) plus
534 controls.
All patients met the revised 2002 American-European
consensus research classification criteria for pSS [1].
Anti-Ro±La status was performed as part of routine
diagnosis, and was available for all patients. Autoanti-
body testing using recombinant protein was performed
by ELISA in cohort 1 [4], and by immunodiffusion in
cohort 2 [34]. The majority of patients were autoanti-
body-positive, with 82% of pSS patients from the first
cohort, and 71% of pSS patients from the second cohort
positive for anti-Ro±La.
HLA DR3 status was available for all patients and con-
trols for cohort 1 (medium resolution DRB1 genotyping
performed by the Tissue Typing Laboratory, Adelaide
Red Cross Blood Transfusion Service, South Australia),
and for the majority of pSS patients from cohort 2 (a
DR3 sequence-specific priming assay). A DR3 proxy
SNP, rs2187668 [35], was used for analyses of the con-
trols from cohort 2. The use of the minor allele of
rs2187668 as a proxy for DR3 was validated against indi-
viduals with known DR3 status in each cohort, with
observed kappa agreements of 0.95, and 0.92 respec-
tively (data not shown).
The study was approved by the Human Ethics Com-
mittees of The Queen Elizabeth Hospital, the Sydney
West Area Health Service and OMRF, in accordance
with the Helsinki Declaration, and all participants gave
informed, written consent.
P2RX7 SNP genotyping
Twelve SNPs (one intron splice site, and eleven non-
synonymous) throughout the P2RX7 gene, most of which
have been previously characterised as exerting either loss-
or gain-of- function over the wild-type receptor, were
examined in pSS patients and controls from cohort 1
(Table 1). Eight SNPs were analysed by high-throughput
TaqManTM genotyping assays performed on an ABI
Prism ABI Prism®7900HT sequence detection system
(Applied Biosystems, Foster City, CA, USA) at the SUPA-
MAC Facility, Royal Prince Alfred Hospital, Sydney,
Australia. G1068A was genotyped using the commercial
TaqManTM assay, C_11704039_10 (Applied Biosystems).
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SNPs G151T, G474A, G946A, C1096G, A1405G, A1513C
and T1729A were genotyped using primers and probes as
listed in Additional file 1, Table S1. Four SNPs, T253C,
C489T, G835A and G853A were genotyped by a homoge-
neous mass extension assay at the Australian Genome
Research Facility (St Lucia, Queensland).
Genotype data for the P2X7 A1405G SNP (rs2230912)
and the DR3 proxy, rs2187668 were obtained for cohort
2 using the Illumina OMNI-1 Quad array (San Diego,
CA, USA) following manufacturer’s protocols. These sub-
jects were also evaluated for possible population stratifi-
cation using principal component analysis implemented
in Eiganstrat [36] utilizing approximately 30,000 indepen-
dent SNPs (r2 <0.20) scattered thought the genome.
Samples were plotted alongside the HapMap populations
to determine which ones were genetic outliers.
Serum IL-18 assays
Serum IL-18 levels were assayed by sandwich ELISA
(Human IL-18 ELISA Kit, Medical and Biological
Laboratories Company Limited, Nagaoya, Japan, catalo-
gue number 7620), according to the manufacturer’s
instructions.
P2X7 function measured by ATP-induced ethidium
uptake (pore assay)
Peripheral venous blood was obtained from healthy
volunteers and mononuclear cells were isolated by Ficoll-
Paque gradient centrifugation. P2X7 receptor function
was measured by the ATP-induced ethidium+ uptake in
a mixed cell (B and T lymphocytes and monocytes) sus-
pension using time-resolved two-colour flow cytometry
[37]. Briefly, mononuclear cells were labelled with a phy-
coerythrin (PE)-conjugated monoclonal antibody to CD3
and an allophycocyanin (APC)-conjugated monoclonal
antibody to CD14 (Dako). Ethidium+ (25 μM) was added
to a cell suspension maintained at 37°C with stirring in a
time-zero module, and 1 mM ATP was added 40 s later.
The cells were analysed at 1000 events/s on a FACSCali-
bur flow cytometer and gated by forward and side scatter
and by cell type-specific monoclonal antibody. The linear
mean channel of fluorescence intensity for each gated
subpopulation over successive 10-s intervals was analysed
by WinMDI version 2.8 software [38] and plotted against
time to estimate the maximum rate of ethidium+ uptake.
The linear portion of the ethidium+ uptake plot was used
for slope calculations over a period of 1 minute.
Statistical analysis
Differences in allele frequencies between patients and
controls were analysed by logistic regression using the
default additive model for allele coding and odds ratios
(OR) were derived from exponentiation of the regression
coefficients. Epistasis was analysed using a two-factor
interaction logistic regression model, with the signifi-
cance of the epistasis determined by the significance of
the coefficient for the interaction term. Analyses for
cohort 2 were ancestry-adjusted by the inclusion of the
principal components as covariates. Serum IL-18 levels
were log-normally distributed and were therefore analysed
by lognormal regression and data presented as medians.
These analyses were performed using Statistica v6.1 (Stat-
Soft Inc, Tulsa, Oklahoma, USA). Haplotype inference was
performed using Phase version 2 software [39].
Results
Functional P2RX7 polymorphism in pSS patients and
population based controls
The minor allele frequencies for each of the 12 P2RX7
functional SNPs in pSS patients and controls from
cohort 1 are presented in Additional file 1, Table S2.
The minor alleles of five SNPs (G151T, G474A, G853A,
G946A and T1729A) were rare (frequency <5%). There
was no evidence of an association between any of the 12
Table 1 P2RX7 SNPs genotyped in pSS patients and normal subjects
# ID SNP Exon Protein Functional effect of minor allele [30,31,40]
1 rs35933842 G151T 1 Intron 1 splice site Loss
2 rs17525809 T253C 2 V76A Partial loss
3 rs28360447 G474A 5 G150R Loss
4 rs208294 C489T 5 H155Y Gain
5 rs7958311 G835A 8 R270H Partial loss
6 rs7958316 G853A 8 R276H Loss
7 rs28360457 G946A 9 R307Q Loss
8 rs1718119 G1068A 11 A348T Gain
9 rs2230911 C1096G 11 T357S Partial loss
10 rs2230912 A1405G 13 Q460R Gaina
11 rs3751143 A1513C 13 E496A Loss
12 rs1653624 T1729A 13 I568N Loss
aThe minor allele 1405G is a tag for haplotype 4 (Figure 1). pSS, primary Sjögren’s syndrome; SNP, single nucleotide polymorphism.
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functional SNPs and pSS. However, the frequency of the
minor allele of the A1405G SNP (rs2230912) was quite
discrepant between seronegative and seropositive pSS
patients in cohort 1, and was in fact increased in sero-
positive pSS patients compared to controls (OR = 1.78,
95% CI 1.09, 2.92, P = 0.02) (Table 2). However this
association was not confirmed in cohort 2.
The minor allele of P2RX7 A1405G exhibits a negative
epistatic interaction with HLA DR3 in Ro±La seropositive
pSS patients
We further investigated the role of the A1405G allele in
anti-Ro±La seropositive pSS by considering epistasis
with HLA DR3. The HLA region confers a strong
genetic risk for seropositive pSS, and DRB1 alleles are
markers of this risk. In Caucasian populations, the
strongest association is observed with HLA DR3,
although other DRB1 alleles are also involved, and the
associated alleles are known to differ across different
racial groups.
The joint distribution of HLA DR3 and the P2RX7
1405G allele was examined by a two-factor interaction
logistic regression model in both cohorts. Differences in
the available data in relation to ascertainment of DR3 sta-
tus necessitated several analyses, and the results of the
regression coefficients for these analyses are depicted in
Table 3.
These analyses confirm that HLA DR3 is a strong risk
factor for seropositive, but not seronegative pSS. However
this association with DR3 appears somewhat greater in
cohort 1 compared to cohort 2, which used a proxy SNP
for DR3 status. For example, the regression coefficients
(log-OR) reported in Table 3 equate to OR of 9.3 (95% CI
4.5, 19.2) for cohort 1, compared to 2.6 (95% CI 2.6, 5.8)
for cohort 2. Further, there is remarkably consistent evi-
dence of a statistically significant negative epistatic interac-
tion between HLA DR3 (or proxy) and the P2RX7 1405G
allele in seropositive pSS patients, whether comparing
these patients to controls (in both cohorts), or seropositive
pSS to seronegative pSS patients (sufficient data for cohort
2 only) (Table 3). This negative epistasis, which is assessed
by b3 coefficient in Table 3, implies that the proportion of
seropositive pSS patients who carry both alleles is signifi-
cantly less than expected. However, the association
between the P2RX7 1405G allele and seropositive pSS
patients who do not carry DR3 (the b2 coefficient in Table
3) observed in cohort 1 (OR 3.0, 95% CI 1.4, 6.4) was not
replicated in cohort 2 (OR 1.3, 95% CI 0.8, 2.0). This epis-
tasis effect with DR3 was specific for the P2RX7 1405G
allele, and was not observed with any other P2RX7 SNPs
genotyped in cohort 1 (data not shown).
The most plausible interpretation of these findings is
that the P2RX7 1405G allele is a risk factor for seroposi-
tive pSS in a specific subgroup of patients who do not
carry HLA risk alleles, but confers no additional risk in
individuals who do. In our analysis, the use of HLA
DR3 would only partially adjust for the HLA risk, as
other DRB1 alleles are also involved [3]. Given that the
OR for the association with DR3 are greater in cohort 1
than in cohort 2 (Table 3), this implies that other DRB1
alleles may be relatively more important in cohort 2, yet
the analysis could not adjust for this. This difference in
HLA risk adjustment between cohorts may be sufficient
to explain the lack of replication of the P2RX7 1405G
allele association in cohort 2 (Table 3).
The 1405G allele is a tag for a common P2RX7 haplotype
There was evidence of strong linkage disequilibrium
between the P2RX7 SNPs. Haplotype reconstruction of
pSS patients in cohort 1 and controls identified six major
haplotypes (individual frequencies greater than 5%), with a
combined frequency of 70% (Figure 1). These haplotypes
and frequencies are comparable to those identified in a
large Australian Caucasian cohort [30,31]. Importantly,
the 1405G minor allele was observed on only one major
haplotype (haplotype 4, frequency 13%), and this minor
allele is therefore a tag for haplotype-4 which also carries
minor alleles for both C489T and G1068A.
The 1405G allele is associated with gain-of-function of
the P2X7 receptor
P2X7 receptor function associated with the A1405G
polymorphism was studied in monocytes and lympho-
cytes from peripheral blood of healthy individuals by
Table 2 Frequency of the minor allele of P2RX7 A1405 G allele in pSS patients and controls
Cohort Group Number A1405G MAFa Odds ratio (95% CI) P-value
Cohort 1 Controls 136 0.15 1
All pSS 114 0.20 1.46 (0.91, 2.34) 0.12
Seronegative pSS 19 0.07 0.44 (0.13,1.52) 0.22
Seropositive pSS 95 0.23 1.78 (1.09, 2.92) 0.02
Cohort 2 Controls 534 0.15 1
All pSS 281 0.17 1.07 (0.79, 1.45)b 0.64
Seronegative pSS 82 0.21 1.35 (0.87, 2.10) b 0.18
Seropositive pSS 199 0.16 0.96 (0.68, 1.36) b 0.83
aMAF, minor allele frequency; bprincipal components adjusted analysis; pSS, primary Sjögren’s syndrome.
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measuring membrane pore formation (assessed by ethi-
dium uptake), following receptor activation by ATP.
Monocytes from individuals homozygous or heterozy-
gous for the 1405G allele exhibited an increase in ATP-
induced ethidium uptake compared with monocytes
from homozygous 1405AA individuals (P = 0.018, n = 5
to 18 individuals) (Figure 2A, C), indicative of a gain in
receptor function associated with the 1405G allele. Simi-
lar results were obtained with T-lymphocytes, where
cells from 1405AG heterozygous individuals, exhibited
an increased ATP-induced ethidium uptake (P = 0.015,
n = 5 to 16 subjects) (Figure 2B, D). These results con-
firm previous reports that the 1405G allele is associated
with gain of P2X7 receptor function [40].
Serum IL-18 levels are increased in pSS patients with
Ro/La autoantibodies
IL-18 is a downstream cytokine released following P2X7
receptor activation, and serum IL-18 levels were mea-
sured in 72 pSS patients (54 seropositive for anti-Ro±La
autoantibodies) and 36 age- and gender-matched con-
trols from cohort 1 (Figure 3). When analysed by log-
normal regression, mean serum IL-18 levels (in pg/mL)
were 339, 318, and 498 for the controls, seronegative
pSS and seropositive pSS patients, respectively. Serum
IL-18 levels were almost 50% higher in Ro/La autoanti-
body-positive pSS patients compared to normal subjects
(ratio = 1.47, 95% CI 1.22, 4.26, P < 0.001), consistent
with previous reports. In contrast, the serum IL-18
levels in seronegative pSS patients were not different to
that observed in normal controls (ratio = 1.12, 95% CI =
0.87, 1.45, P = 0.4). Among the seropositive pSS
patients, there was no difference between the median
IL-18 level in patients who carried the 1405G allele (549
pg/mL, n = 25) compared to patients with 1405A (460
pg/mL, n = 29, P = 0.13). There was no evidence of any
influence of HLA DR3 status on IL-18 levels in these
patients.
Discussion
Autoantibodies, which target intracellular antigens, are a
feature of systemic autoimmune diseases such as pSS.
These autoantibodies react with autoantigen exposed on
apoptotic or necrotic cells, or their debris, and resulting
immune complexes promote chronic systemic inflam-
mation via upregulation of the type I interferon system
[2]. Delayed or defective clearance of apoptotic/necrotic
cellular debris is understood to be an important factor
Table 3 Epistasis between P2RX7 1405G and HLA DR3 in anti Ro±La seropositive primary Sjögren’s syndrome (pSS)
Seropositive pSS (n = 95)
versus controls (n = 136)
Seropositive pSS (n = 199)
versus controls (n = 534)
Seropositive (n = 191) versus
seronegative pSS (n = 80)
Seronegative pSS (n = 82)
versus controls (n = 534)
Cohort 1: DRB1-typing Cohort 2: DR3 proxy SNPa Cohort 2: DR3 SSPa Cohort 2: DR3 proxy SNPa
Term b SE P b SE P b SE P b SE P
b0 (Intercept 1) -1.64 0.28 <0.001 -0.01 2.64 1 -3.97 4.31 0.36 1.04 3.32 0.75
b1 (DR3-pos) 2.23 0.37 <0.001 1.35 0.21 <0.001 1.39 0.37 <0.001 0.28 0.33 0.40
b2 (P2RX7_1405G) 1.11 0.38 0.003 0.26 0.22 0.24 0.25 0.34 0.46 0.29 0.27 0.28
b3 (DR3*1405G) -1.27 0.53 0.016 -0.76 0.35 0.027 -1.27 0.56 0.023 0.02 0.47 0.96
aAnalysis performed using principle components adjustment for possible ancestry differences. The combined effect of these alleles was examined by two-factor
interaction logistic regression (DR3*1405G) in both cohorts for the data tabulated in Additional File 1, Table S3. DR3 was coded positive (pos) or negative, and
additive genetic coding was used for 1405G. The regression coefficients b1 and b2 represent the loge odds ratios for individuals who carry DR3 alone and 1405G
alone, relative to individuals who carry neither. The interaction term, b3, represents the deviation from the expected log odds ratio for individuals who carry both
alleles, and is the test for epistasis between 1405G and DR3. Different analyses were required to accommodate differences in the available data for DR3 status.
The results demonstrate that DR3 (b2), or proxy, is a significant risk factor for seropositive pSS, but not seronegative pSS. Further, there is a negative epistatic
interaction between DR3 (or proxy) and P2RX7 1405G (b3) specifically in seropositive pSS. However, the association of the 1405G allele with seropositive pSS (in
the absence of DR3, b2), observed in Cohort 1, was not replicated in Cohort 2. SE, standard error.
Figure 1 Common (>5% frequency) P2RX7 haplotypes identified in the study population. Grey squares represent the major alleles and
black squares the minor alleles, for each single nucleotide polymorphism. Numbering of polymorphisms are based on the original mRNA
sequence [Y09561.1; GenBank]. Six major haplotypes were identified with a combined frequency of 70%.
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Figure 2 Human peripheral blood mononuclear cells were analysed for ATP-induced ethidium uptake using time-resolved flow
cytometry. Monocytes were identified by an anti-CD14 APC antibody and T lymphocytes were identified by an anti-CD3-PE antibody. Ethidium
uptake (25 μM) was measured in response to P2X7 receptor stimulation by 1mM ATP. (A) and (C) are representative ethidium uptake curves
from genotyped individuals. (B) and (D) are scattergrams of collated data from 5 to 18 subjects from each genotype group (number of subjects
shown in brackets) with ATP-induced ethidium uptake calculated from the slope of the linear portion of the uptake plot over 1 minute. *P <
0.05 from one-way analysis of variance with Dunnett’s post hoc test.
Figure 3 Boxplots of serum IL-18 levels (pg/mL) in controls (n = 36), autoantibody negative pSS (n = 18), and autoantibody positive
primary Sjögren’s syndrome (pSS) (n = 54). Serum IL-18 levels were significantly different between the three groups (P = 0.0003, Kruskal-
Wallis test), and highest in autoantibody-positive pSS.
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in the breakdown of self-tolerance and ongoing immune
complex mediated inflammation [41]. Ro±La autoanti-
bodies are typically present in the majority of pSS
patients (70 to 82% in the present study) and are asso-
ciated with higher levels of glandular inflammation, and
extraglandular features such as vasculitis, interstitial
lung disease and lymphoma [42]. There is increasing
evidence that autoantibody-positive pSS has different
genetic risk factors to autoantibody-negative pSS [3,4],
which possibly reflects different mechanisms of disease
pathogenesis.
In this study we examined the interaction of the pro-
inflammatory P2X7 receptor in the pathogenesis of
Ro±La autoantibody-positive pSS (seropositive pSS) in
two cohorts. The primary focus was on the P2RX7
1405G allele, which is a tag for a common haplotype
conferring gain-of-function on the P2X7 receptor
[30,31]. This haplotype also carries minor alleles from
two other SNPS, 489T and 1068A (Table 1, Figure 1),
and analysis of the functional effects of each in isolation
suggests that they contribute, in an additive way, to the
increased receptor function observed with this haplotype
[30,43]. We have demonstrated an interaction between
this gain of function SNP/haplotype and seropositive
pSS, whereas no associations were observed with loss of
function SNPs/haplotypes. Previous studies of P2RX7
polymorphism and systemic autoimmune disease have
reported no association between the A1513C loss-of-
function SNP in Caucasian patients with SLE or RA
[44,45], which is consistent with the results of the pre-
sent study.
We observed a remarkably consistent negative epi-
static interaction between P2RX7 1405G and HLA DR3,
the primary genetic risk factor for pSS, in two cohorts
of seropositive pSS patients. This negative epistatic
interaction was present when seropositive pSS patients
were either compared to controls, or to seronegative
pSS patients, so that the combined risk for individuals
who carry both genetic factors is somewhat less than
expected. In cohort 1 we also observed that the P2RX7
1405G allele is a risk factor for seropositive pSS in indi-
viduals who do not carry HLA DR3, but this effect was
not replicated in cohort 2. The analysis in cohort 2
included principal components (derived from unrelated
genetic markers) as covariates to adjust for possible
population stratification, which can cause spurious asso-
ciations in disease studies [36]. Therefore, the observed
epistasis cannot be attributed to systematic ancestry dif-
ferences between cases and controls.
The most plausible interpretation of these findings is
that the P2RX7 1405G allele is a risk factor for seroposi-
tive pSS in a specific subgroup of patients who do not
carry HLA risk alleles, but confers no additional risk in
individuals who do, and that differences in results
between the cohorts may reflect differences in adjust-
ment for the HLA associated risk, which is only partially
reflected by DR3 status. For example, it is unclear
whether the use of a surrogate SNP for determining
HLA-DR3 status in the cohort 2 controls may have influ-
enced the results by underestimating the prevalence of
HLA-DR3; further, HLA-DR2 is also associated with
autoantibody-positive pSS [3], but this information was
not available for cohort 2.
The epistatic interaction between DR3 and the P2RX7
1405G allele in seropositive pSS implies overlap in
pathogenic mechanisms associated with these alleles.
Unfortunately, the pathogenic mechanisms underlying
HLA-associated disease susceptibility are not under-
stood, therefore, the interpretation is highly speculative.
We propose that the observed epistasis between DR3
and the P2RX7 1405G allele may reflect increased auto-
antigen exposure as a susceptibility mechanism for sero-
positive pSS.
Complement deficiency is implicated in the defective
clearance of apoptotic/necrotic debris and, therefore,
increased autoantigen exposure, in systemic autoimmune
disease [46]. It has been proposed that this mechanism
may contribute to some of the pSS disease susceptibility
associated with HLA DR3, which is in linkage disequili-
brium with a C4 null allele [47]. P2X7 receptor activation
may also contribute to increased autoantigen exposure in
systemic autoimmunity. In the presence of the ATP
ligand, P2X7 receptor activation may result in the induc-
tion of cell membrane blebbing and release of micropar-
ticles. Prolonged activation of the P2X7 receptor by ATP
results in cell death with both apoptotic/necrotic features
[13,14], which has also been demonstrated in rat parotid
acinar ParC5 cells [48], accompanied by autoantigen clea-
vage [49]. Importantly, the A1513C loss of function SNP
is associated with a decrease in ATP-induced apoptosis
in CD4(+) lymphocytes isolated from SLE patients [45],
although the gain-of-function polymorphism has not yet
been evaluated. Membrane microparticles released by the
P2X7-induced blebbing process contain not only P2X7
receptors but also Ro-52, a component of the P2X7
membrane complex both in THP-1 macrophages and
transfected HEK-293 epithelial cells [10], and also a tar-
get of autoantibodies in pSS. Further, we have recently
demonstrated that P2X7, in the absence of ATP, acts as a
scavenging receptor for apoptotic cellular debris [50],
although the downstream effects of this have not been
elucidated.
In addition to the genetic epistasis, our data suggest
that there is P2X7 receptor activation in seropositive
pSS. Activation of P2X7 is known to lead to processing
and secretion of pro-inflammatory cytokines IL-1b and
IL-18 from monocyte/macrophages via activation of the
NALP3 inflammasome, which is thought to play a role
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in a spectrum of inflammatory diseases [51], including
rheumatic inflammatory diseases [52]. We have demon-
strated elevated serum IL-18 levels in Ro±La autoanti-
body-seropositive pSS patients, and activation of the
NALP3 inflammasome, via P2X7, may be one of the
mechanisms involved. There was no evidence for an
effect of DR3 or 1405G status on IL-18 levels, although
patient numbers were limited. Previous studies in sys-
temic inflammatory diseases have demonstrated that the
ATP-induced monocyte P2X7 receptor response (as
measured by IL-1b secretion) is attenuated in SLE, but
enhanced in RA [45,53], and that this response is influ-
enced by P2RX7 polymorphism. However, the A1405G
SNP has not been evaluated in this context.
Aside from its pro-inflammatory effects, ATP activa-
tion of the P2X7 receptor has also emerged as an
important regulator of autonomic function, including
salivary gland secretion. While P2X7 receptor activation
can stimulate secretion in mouse submandibular bands,
activation also results in the inhibition of muscarinic
receptor-induced fluid secretion [19]. Therefore, activa-
tion of P2X7 in the milieu of salivary gland inflamma-
tion in pSS may contribute to the failure of fluid
secretion irrespective of the extent of glandular destruc-
tion, through interference of autonomic signalling, a
well-documented phenomenon in pSS. This dysregula-
tion of autonomic function may also be implicated in
the clustering of autonomic symptoms we have pre-
viously reported in pSS [54], and further research into
the role of P2X7 and autonomic dysfunction in pSS is
warranted.
Conclusions
In summary, we have identified that the P2RX7 1405G
gain-of-function allele exhibits a negative epistatic inter-
action with HLA DR3 on the risk of autoantibody-posi-
tive pSS. This, coupled with other studies, implicates
P2X7 receptor function in the pathogenesis of primary
Sjogren’s syndrome.
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